Open AccessComparative efficacy of antiangiogenic treatment for newly diagnosed glioblastoma
Author(s) -
Yuanli Zhao,
Chao Li,
Zhaolun Cai,
Lianwang Li,
Liudong Wei,
Zenghui Qian,
Dabiao Zhou
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000020011
Subject(s) - medicine , medline , bevacizumab , clinical trial , glioblastoma , meta analysis , randomized controlled trial , oncology , evidence based medicine , protocol (science) , intensive care medicine , alternative medicine , pathology , chemotherapy , cancer research , political science , law
Background: Glioblastoma is the most common malignant primary brain tumor which has highly expressed vascular endothelial growth factor. To date, various antiangiogenic drugs have been investigated in clinical trials but with no overall conclusion, especially for newly diagnosed glioblastoma (nGBM). In this study, Bayesian network meta-analysis will be used to conduct a comprehensive analysis of the results of different clinical trials, and assess the efficacy of different antiangiogenic drugs on nGBM. Methods: In order to find more comprehensive information about the application of antiangiogenic drugs in nGBM patients, we searched the MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials for relevant randomized controlled trials. We also reviewed their reference lists to avoid omissions. Cochrane risk of bias tool (V.1.4.3) and Stata (V.15.0) will be used to assess the methodological quality of this review. Results: This study will provide reliable evidence for different antiangiogenic therapies in nGBM patients. Conclusion: We will evaluate the relative effectiveness of different antiangiogenic drugs and rank each intervention in nGBM patients through prognosis to provide decision-making reference on which method to choose for clinicians. Protocol registration number: CRD42019146537